A review of CT-P13: An infliximab biosimilar

BioDrugs

Volumn 28, Issue 3, 2014, Pages 313-321

  McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CT P 13; GENERIC DRUG; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOSIMILAR AGENT; CT-P13; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; BACTERIAL INFECTION; BIOEQUIVALENCE; COST CONTROL; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFUSION RELATED REACTION; MYCOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; TUBERCULOSIS; ULCERATIVE COLITIS; URINARY TRACT INFECTION; ANIMAL;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; HUMANS;

EID: 84901920947     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-014-0094-1     Document Type: Review

References (32)

1. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs); 2009. http://www.who.int/biologicals/areas/ biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed 19 Dec 2013.
2. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Draft; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2013/06/WC500144124.pdf. Accessed 17 Feb 2014.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment report: Inflectra (infliximab); 2013. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002778/ WC500151490.pdf. Accessed 17 Feb 2014.
4. Siddiqui MAA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs. 2005;65:2179-208. (Pubitemid 41478797)
5. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 2002;16(2):111-48. (Pubitemid 34533773)
6. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-12.
7. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-20.
8. Park W, Jaworski J, Brzezicki J, et al. A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the PLANETAS study [abstract no. FRI0421]. 14th Annual Congress of the European League Against Rheumatism, Madrid; 12-15 Jun 2013.
9. Yoo DH, Racewicz A, Brzezicki J, et al. A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study [abstract no. OP0068]. 14th Annual Congress of the European League Against Rheumatism, Madrid; 12-15 Jun 2013.
10. Yoo D, Yagensky A, Toncheva A, et al. Impact of CT-P13 and originator infliximab treatment on quality of life derived from the Health Assessment Questionnaire (AQ) and Short-Form 36 (SF-36) from a randomized, double-blind trial in patients with active RA [abstract no. 2392]. ACR/ARHP Annual Meeting, San Diego; 26-30 Oct 2013.
11. Park W, Miranda P, Brzosko M, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13 [abstract no. L15]. ACR/ARHP Annual Meeting, San Diego; 26-30 Oct 2013.
12. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13 [abstract no. L1]. ACR-ARHP Annual Meeting, San Diego; 26-30 Oct 2013.
13. Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73:198-206.
14. Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Ann Rheum Dis. 2013. doi: 10.1136/annrheumdis-2013-203819.
15. Brodszky V, Pentek M, Baji P, et al. Budget impact analysis of biosimilar infliximab treatment for rheumatoid arthritis in six Central European countries [abstract no. PMS21]. Value Health. 2013;16(7):A558.
16. McCarthy G, Ebel Bitoun C, Guy H. Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland [abstract no. PMS22]. Value Health. 2013;16(7):A558.
17. European Medicines Agency. Remsima: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002576/WC500150871.pdf. Accessed 19 Dec 2013.
18. European Medicines Agency. Inflectra: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002778/WC500151489.pdf. Accessed 19 Dec 2013.
19. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322-8.
20. US Food and Drug Administration. Quality considerations in demonstrating biosimilarity to a reference protein product: draft guidance; 2012. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm291134.pdf. Accessed 13 Jan 2014.
21. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594-602. (Pubitemid 32162982)
22. St Clair EW, Van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-43. (Pubitemid 39488667)
23. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9. (Pubitemid 34621118)
24. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-85. (Pubitemid 38252535)
25. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. (Pubitemid 41770166)
26. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582-91. (Pubitemid 40216323)
27. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52(4):1227-36. (Pubitemid 40530131)
28. Antoni CE, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-7. (Pubitemid 41113349)
29. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534-42. (Pubitemid 39278071)
30. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367-74. (Pubitemid 41443403)
31. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132(3):863-73. (Pubitemid 46454266)
32. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391-9.